ID: ALA75766

Max Phase: Preclinical

Molecular Formula: C20H26N2O4

Molecular Weight: 358.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)N1CCCC(COC(=O)c2ccccc2N2C(=O)CCC2=O)C1

Standard InChI:  InChI=1S/C20H26N2O4/c1-14(2)21-11-5-6-15(12-21)13-26-20(25)16-7-3-4-8-17(16)22-18(23)9-10-19(22)24/h3-4,7-8,14-15H,5-6,9-13H2,1-2H3

Standard InChI Key:  CSZKNYBZEVPEJZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 358.44

Molecular Weight (Monoisotopic): 358.1893

AlogP: 2.62

#Rotatable Bonds: 5

Polar Surface Area: 66.92

Molecular Species: BASE

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.60

CX LogP: 2.19

CX LogD: 0.01

Aromatic Rings: 1

Heavy Atoms: 26

QED Weighted: 0.60

Np Likeness Score: -0.86

References

1. Bergmeier SC, Lapinsky DJ, Free RB, McKay DB..  (1999)  Ring E analogs of methyllycaconitine (MLA) as novel nicotinic antagonists.,  9  (15): [PMID:10465558] [10.1016/s0960-894x(99)00378-9]

2. Bergmeier SC, Ismail KA, Arason KM, McKay S, Bryant DL, McKay DB..  (2004)  Structure activity studies of ring E analogues of methyllycaconitine. Part 2: Synthesis of antagonists to the alpha3beta4* nicotinic acetylcholine receptors through modifications to the ester.,  14  (14): [PMID:15203153] [10.1016/j.bmcl.2004.05.001]

Source

Source(1):

• Scientific Literature